Celon Pharma Sa · GPW:CLN

Celon Pharma Sa — Q3 2023 Earnings Presentation

12 slides from Celon Pharma Sa's earnings presentation, Nov 22, 2023

  1. Slide 1: Investor Presentation 3Q2023

    INVESTOR PRESENTATION 3Q2023 WARSAW // 22.11.2023

  2. Slide 2: Disclaimer

    Neither this presentation (the “Presentation”, references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) nor any copy of it nor the information contained herein is being is

  3. Slide 3: Pharma Financials

    PHARMA FINANCIALS

  4. Slide 4: Group and Segment P&L Details for 9M2023/9M2022

    Group and Segment P&L Details for 9M2023/ 9M2022. 5

  5. Slide 5: Segment dynamics - FY 9M2023/9M2022

    Segment dynamics - FY 9M2023/9M2022 All amounts in million PLN BRANDED GENERICS R&D TOTAL INNOVATIVE PRODUCTS (R&D) Revenues Revenues Revenues 161.7 36.1 139.8 125.5 118.3 21.5 3Q23 3Q22 3Q23 3Q22 3Q23 3Q22 Expenses Expenses Expenses 102.6 83.6 77.1 87.4 179.6 170.9 3Q23 3Q22 3Q23 3Q22 3Q23 3Q22 EBI

  6. Slide 6: Balance sheet

    Balance sheet. A. Expansion of IP rights (Glaxo) for our legacy business division, contracted in 2020. B. Equity stakes in other companies (Mabion) C. Financial resources obtained from the issue of shares and deposited in an investment fund D. Other liabilities in the amount of PLN 20,7m due this an

  7. Slide 7: Branded Generics

    PHARMA BRANDED GENERICS

  8. Slide 8: Revenues 3Q2022-3Q2023 (MLN PLN)

    161,6 Revenues 3Q2022-3Q2023 (MLN PLN) 139,8 Q3 2022 45,0 48,8 Q3 2022 100 +3 +4,3 +17,6 Q2 2022 Q2 2023 52,8 68,4 Q1 2022 41,9 43,9 Q1 2023 0 2022 Domestic Export Grants 2023 sales

  9. Slide 9: Innovative Business

    PHARMA ININGWANIWA= BUSINESS

  10. Slide 10: News Flow & Key Milestones 2023/2024

    News Flow & Key Milestones 2023/2024 Q1 2024 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 CPL’280 end of Phase 2 in diabates CPL’36 end of Phase 2 in both indications CPL’116 end of Phase 2 in RA CPL’116 CPL’280 end of Phase 2 in RA start of Phase 2b in diabetes CPL’280 start of Phase 2 in diabet

  11. Slide 11: Partnering Strategy 2023/2024

    Partnering Strategy 2023/2024* Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 FALKIERI FALKIERI CPLCPL’ 280280 CLP36 CPL’36 CPL116CPL’116 CPL110 CPL’110 Metabolic diseases Oncology Neuropsychiatry Inflamatory diseases Realizacja strategii parteringowej oraz progres rozmów z partnerami jest związany

  12. Slide 12: Q&A

    QA

Celon Pharma — Q3 2023 Earnings Presentation on 6ix